Britain's National Institute of Clinical Excellence (NICE) plans to conduct on an annual basis clinical and cost-effectiveness evaluations of between 30 and 50 new and existing medical technologies, Edward Hutt, division director Quintiles Medical Technology Consultants, said March 14.

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.